16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics Inc. (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
11:33 , Nov 13, 2018 |  BC Extra  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1 pioneer Lieping Chen...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
21:50 , Nov 9, 2018 |  BC Extra  |  Company News

Sangamo slides on delayed readout for hemophilia A gene therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) said on its 3Q18 earnings call late Thursday that it will not submit a late-breaking abstract to present Phase I/II data for its hemophilia A gene therapy at next month's American...
18:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Sandoz gives up on Rituxan biosimilar in U.S.

With two competing biosimilars under FDA review, Sandoz will no longer seek U.S. approval of GP2013, its biosimilar of cancer and autoimmune drug Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). The unit of Novartis AG (NYSE:NVS;...
18:25 , Nov 9, 2018 |  BC Week In Review  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
17:38 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

ViiV's fostemsavir maintains virologic suppression at week 48 in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said fostemsavir plus optimized background therapy maintained virologic suppression of less than 40 copies/mL from week 24 to 48 in 54% of heavily treatment-experienced patients with HIV-1 infection in the...
17:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves AcelRx, Coherus, Pfizer Products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Nov. 2, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....